Disease Markers

Role of the Gas6/TAM System as a Disease Marker and Potential Drug Target


Publishing date
01 Aug 2019
Status
Closed
Submission deadline
15 Mar 2019

1Università degli Studi del Piemonte Orientale, Novara, Italy

1Università degli Studi del Piemonte Orientale, Novara, Italy

2Queen Mary University of London, London, UK

This issue is now closed for submissions.
More articles will be published in the near future.

Role of the Gas6/TAM System as a Disease Marker and Potential Drug Target

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Growth Arrest Specific Gene 6 (Gas6) is the circulating ligand of three tyrosine kinase receptors (TAM) named Axl, Tyro3, and Mer; a mass of evidence has recently linked Gas6 and its receptors to the pathogenesis of different human diseases, characterized by inflammation as well as fibrosis. This finding suggests a possible key role of this system in the delicate regulation of the immune system, of innate immunity in particular, in dampening inflammation, and in favouring tissue repair. Since both Gas6 and the soluble form of TAM receptors (sTAM) are plasma circulating proteins, they have also been proposed as potential biomarkers in different conditions ranging from autoimmune diseases to fibrotic diseases (i.e., hepatic cirrhosis) and acute inflammatory conditions (i.e. sepsis). A deeper insight into this topic might contribute to the linking of basic science and translational research results to their possible clinical implications.

This special issue aims to improve our knowledge about the involvement of this biological system in human disease. We especially encourage the submission of papers focused on the potential role of this system in the pathogenesis of inflammatory disorders and evaluating Gas6 and TAM receptors as diagnostic/prognostic biomarkers of human diseases. Original research articles as well as review articles focusing on the current state-of-the-art are welcome.

Potential topics include but are not limited to the following:

  • Anti-inflammatory and antifibrogenic activities of Gas6/TAM receptors system
  • Gas6/TAM receptors in systemic lupus erythematosus
  • Gas6/TAM receptors as a biomarker of organ involvement in systemic sclerosis
  • Gas6/TAM receptors in rheumatoid arthritis
  • Gas6 as a biomarker of chronic liver diseases
  • Gas6/TAM receptors in neuroimmunology
  • Gas6/TAM system in interstitial lung disease
  • Role of Gas6/TAM receptors in diabetes
  • Gas/axl in solid malignancies
  • Gas6 and acute inflammation and sepsis
Disease Markers
 Journal metrics
Acceptance rate34%
Submission to final decision87 days
Acceptance to publication43 days
CiteScore2.640
Impact Factor2.761
 Submit